Epidermal growth factor receptor mutations as a prognostic factor in korean patients with advanced lung adenocarcinoma who had not been treated with received epidermal growth factor receptor tyrosine kinase inhibitors

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Epidermal growth factor receptor (EGFR) mutations as prognostic marker in patients with non-small cell lung cancers remain controversial. In particular, there is only a limited amount of data on the subject in Asian patients with advanced lung adenocarcinomas. Patients and Methods: We analyzed 50 patients with advanced lung adenocarcinoma, who received best supportive care with and without cytotoxic chemotherapy, between March 2006 and December 2008. The patients had never been treated with EGFR tyrosine kinase inhibitors. Tumor tissues of all 50 patients were analyzed for the status of EGFR gene mutations. Results: The median age of patients was 64 years (range 32-84) at diagnosis, and the male/female ratio was 2.6/1.0. Thirty-two patients were current or ever smokers. EGFR gene mutations were detected in 11 patients (22%). Seven of them had in-frame deletion within exon 19, resulting in the loss of codon 746 through 750 (delE746-A750), 2 patients had L858R in exon 21, and 2 patients had point mutation at codon 709 in exon 18, resulting in the substitution of glycine either with glutamic acid or alanine. The status of EGFR mutations was not significantly associated with gender, smoking status, ages, metastatic sites and number of metastasized sites. Seventeen patients received best supportive care without cytotoxic chemotherapy and 33 patients received the standard platinum-based doublet chemotherapy. The median overall survival was 8.90 months (95% CI 4.01-13.79). There were no significant differences in overall survival (p = 0.282) according to the status of EGFR mutations. Conclusion: These results suggest that EGFR mutation is not a prognostic marker in Korean patients with advanced lung adenocarcinoma who had not been treated with EGFR tyrosine kinase inhibitors.

Original languageEnglish
Pages (from-to)108-114
Number of pages7
JournalChemotherapy
Volume57
Issue number2
DOIs
Publication statusPublished - 2011 Apr 1

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Mutation
erbB-1 Genes
Exons
Adenocarcinoma of lung
Drug Therapy
Codon
Survival
Platinum
Point Mutation
Non-Small Cell Lung Carcinoma
Alanine
Glycine
Glutamic Acid
Smoking

Keywords

  • Epidermal growth factor receptor mutation
  • Lung adenocarcinoma
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery

Cite this

@article{9fbd48637da449ad88360ce65e3acd15,
title = "Epidermal growth factor receptor mutations as a prognostic factor in korean patients with advanced lung adenocarcinoma who had not been treated with received epidermal growth factor receptor tyrosine kinase inhibitors",
abstract = "Background: Epidermal growth factor receptor (EGFR) mutations as prognostic marker in patients with non-small cell lung cancers remain controversial. In particular, there is only a limited amount of data on the subject in Asian patients with advanced lung adenocarcinomas. Patients and Methods: We analyzed 50 patients with advanced lung adenocarcinoma, who received best supportive care with and without cytotoxic chemotherapy, between March 2006 and December 2008. The patients had never been treated with EGFR tyrosine kinase inhibitors. Tumor tissues of all 50 patients were analyzed for the status of EGFR gene mutations. Results: The median age of patients was 64 years (range 32-84) at diagnosis, and the male/female ratio was 2.6/1.0. Thirty-two patients were current or ever smokers. EGFR gene mutations were detected in 11 patients (22{\%}). Seven of them had in-frame deletion within exon 19, resulting in the loss of codon 746 through 750 (delE746-A750), 2 patients had L858R in exon 21, and 2 patients had point mutation at codon 709 in exon 18, resulting in the substitution of glycine either with glutamic acid or alanine. The status of EGFR mutations was not significantly associated with gender, smoking status, ages, metastatic sites and number of metastasized sites. Seventeen patients received best supportive care without cytotoxic chemotherapy and 33 patients received the standard platinum-based doublet chemotherapy. The median overall survival was 8.90 months (95{\%} CI 4.01-13.79). There were no significant differences in overall survival (p = 0.282) according to the status of EGFR mutations. Conclusion: These results suggest that EGFR mutation is not a prognostic marker in Korean patients with advanced lung adenocarcinoma who had not been treated with EGFR tyrosine kinase inhibitors.",
keywords = "Epidermal growth factor receptor mutation, Lung adenocarcinoma, Tyrosine kinase inhibitors",
author = "Kim, {Seung Tae} and Choi, {Yoon Ji} and Park, {Kyong Hwa} and Oh, {Sang Cheul} and Seo, {Jae Hong} and Shin, {Sang Won} and Kim, {Jun Suk} and Kim, {Yeul Hong}",
year = "2011",
month = "4",
day = "1",
doi = "10.1159/000321490",
language = "English",
volume = "57",
pages = "108--114",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Epidermal growth factor receptor mutations as a prognostic factor in korean patients with advanced lung adenocarcinoma who had not been treated with received epidermal growth factor receptor tyrosine kinase inhibitors

AU - Kim, Seung Tae

AU - Choi, Yoon Ji

AU - Park, Kyong Hwa

AU - Oh, Sang Cheul

AU - Seo, Jae Hong

AU - Shin, Sang Won

AU - Kim, Jun Suk

AU - Kim, Yeul Hong

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Background: Epidermal growth factor receptor (EGFR) mutations as prognostic marker in patients with non-small cell lung cancers remain controversial. In particular, there is only a limited amount of data on the subject in Asian patients with advanced lung adenocarcinomas. Patients and Methods: We analyzed 50 patients with advanced lung adenocarcinoma, who received best supportive care with and without cytotoxic chemotherapy, between March 2006 and December 2008. The patients had never been treated with EGFR tyrosine kinase inhibitors. Tumor tissues of all 50 patients were analyzed for the status of EGFR gene mutations. Results: The median age of patients was 64 years (range 32-84) at diagnosis, and the male/female ratio was 2.6/1.0. Thirty-two patients were current or ever smokers. EGFR gene mutations were detected in 11 patients (22%). Seven of them had in-frame deletion within exon 19, resulting in the loss of codon 746 through 750 (delE746-A750), 2 patients had L858R in exon 21, and 2 patients had point mutation at codon 709 in exon 18, resulting in the substitution of glycine either with glutamic acid or alanine. The status of EGFR mutations was not significantly associated with gender, smoking status, ages, metastatic sites and number of metastasized sites. Seventeen patients received best supportive care without cytotoxic chemotherapy and 33 patients received the standard platinum-based doublet chemotherapy. The median overall survival was 8.90 months (95% CI 4.01-13.79). There were no significant differences in overall survival (p = 0.282) according to the status of EGFR mutations. Conclusion: These results suggest that EGFR mutation is not a prognostic marker in Korean patients with advanced lung adenocarcinoma who had not been treated with EGFR tyrosine kinase inhibitors.

AB - Background: Epidermal growth factor receptor (EGFR) mutations as prognostic marker in patients with non-small cell lung cancers remain controversial. In particular, there is only a limited amount of data on the subject in Asian patients with advanced lung adenocarcinomas. Patients and Methods: We analyzed 50 patients with advanced lung adenocarcinoma, who received best supportive care with and without cytotoxic chemotherapy, between March 2006 and December 2008. The patients had never been treated with EGFR tyrosine kinase inhibitors. Tumor tissues of all 50 patients were analyzed for the status of EGFR gene mutations. Results: The median age of patients was 64 years (range 32-84) at diagnosis, and the male/female ratio was 2.6/1.0. Thirty-two patients were current or ever smokers. EGFR gene mutations were detected in 11 patients (22%). Seven of them had in-frame deletion within exon 19, resulting in the loss of codon 746 through 750 (delE746-A750), 2 patients had L858R in exon 21, and 2 patients had point mutation at codon 709 in exon 18, resulting in the substitution of glycine either with glutamic acid or alanine. The status of EGFR mutations was not significantly associated with gender, smoking status, ages, metastatic sites and number of metastasized sites. Seventeen patients received best supportive care without cytotoxic chemotherapy and 33 patients received the standard platinum-based doublet chemotherapy. The median overall survival was 8.90 months (95% CI 4.01-13.79). There were no significant differences in overall survival (p = 0.282) according to the status of EGFR mutations. Conclusion: These results suggest that EGFR mutation is not a prognostic marker in Korean patients with advanced lung adenocarcinoma who had not been treated with EGFR tyrosine kinase inhibitors.

KW - Epidermal growth factor receptor mutation

KW - Lung adenocarcinoma

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=79952590496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952590496&partnerID=8YFLogxK

U2 - 10.1159/000321490

DO - 10.1159/000321490

M3 - Article

VL - 57

SP - 108

EP - 114

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 2

ER -